公开(公告)号：US10106556B2

公开(公告)日：2018-10-23

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Tatsuki Koike ,  Jumpei Aida ,  Makoto Fushimi ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Masako Miyazaki ,  Hidekazu Tokuhara ,  Yasushi Hattori ,  Makoto Kamata

IPC: C07D498/04 ,  C07D413/14 ,  C07D401/06 ,  C07D413/06 ,  C07D417/14 ,  C07D471/04 ,  C07D401/10 ,  C07D413/10 ,  C12N9/99 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.